[ad_1]
The company, which is developing the vaccine in collaboration with the University of Oxford, is leading the global race for the COVID-19 vaccine.
“Ongoing randomized controlled trials of the Oxford Coronavirus Worldwide Vaccine activated our standard evaluation process and voluntarily stopped vaccination so that an independent committee can evaluate the safety data,” said an AstraZeneca spokesperson.
“This is a routine action that should take place when potentially unexplained illness occurs in one of the tests while it is being investigated, ensuring that we maintain the integrity of the tests,” the company said.
It is not yet clear in which country the vaccinated volunteer became ill, what the disease is and how serious it is.
The discontinuation of clinical vaccine trials is not uncommon, but it is considered to be the first trial of a COVID-19 vaccine to be discontinued.
AstraZeneca is one of nine companies that have begun testing phase III vaccines against COVID-19.
As of August 31. the company began vaccinating 30,000. volunteers in the United States.
The vaccine, AZD1222, uses an attenuated version of the cold-causing adenovirus that has been genetically modified to produce a protein that allows the SARS-CoV-2 coronavirus to invade human cells.
After vaccination, this protein is produced in the human body, allowing the immune system to attack the coronavirus if the person becomes infected later.
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
